Breaking news on colorectoral_cancer
Dutch Authorize Manufacture Of Vaccinogen's New Anti-Colon Cancer Vaccine; License Clears Path To European Production, Final FDA Trial published
Thu, 08 May 2008 02:00:00 PDT
Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path to more than US$100 million of potential European sales.The Dutch approval of the company's facility based in Emmen, The Netherlands also paves the way to its pivotal US FDA Phase IIIb clinical trial -- the final step before the vaccine can be sold in the United States.
Curis Announces Genentech's Initiation Of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer published
Wed, 07 May 2008 02:00:00 PDT
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, in metastatic colorectal cancer. As a result, Genentech will make a $3 million cash payment to Curis under the companies' June 2003 collaboration agreement.
Similar Outcomes For Minimally Invasive, Open Surgery In Colon Cancer published
Wed, 07 May 2008 00:00:00 PDT
Large, open incisions that cause pain and require lengthy healing times might be unnecessary to treat colorectal cancer patients successfully, according to a new review of studies."For a long time, many surgeons have been afraid that laparoscopy might impair survival in colorectal cancer patients and cause metastases in the skin openings that are used to insert the instruments, but this has proven not to be the case," said lead reviewer Esther Kuhry, M.D.
Poniard Pharmaceuticals Completes Enrollment Of Phase 2 Picoplatin Trial In Colorectal Cancer published
Wed, 07 May 2008 00:00:00 PDT
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating picoplatin combination chemotherapy for the first-line treatment of metastatic colorectal cancer (CRC). Early data from this trial are expected in the second half of 2008.
Novel Mechanism For The Development Of Colon Cancer Discovered published
Tue, 06 May 2008 05:00:00 PDT
Recent work from the Finnish Academy Center of Excellence on Cancer Biology at the University of Helsinki, Finland, has shed light on the mechanisms of colon tumor development and may help to design better treatment for this disease.Colon cancer is one of the most common malignancies in Western countries: both men and women face a lifetime risk of nearly 6% for the development of invasive colorectal cancer.
Monoclonal Antibody Hb3: A Marker For Colon Cancer Progression Or As A Therapeutic Target? published
Sun, 04 May 2008 03:00:00 PDT
There are a number of researchers who are searching for useful tumor markers to indicate cure. Antigens are being applied as an effective target in clinical therapy. Hb3 is an anti-colorectal cancer monoclonal antibody produced in the researchers' laboratory, and whose sensitivity and specificity are superior to that of anti-CEA. Previous results have showed that CA-Hb3 may be useful in the clinical diagnosis of colorectal cancer.
Studies Point To Benefits Of Personalized Chemotherapy Dose Management In Colorectal Cancer published
Sat, 03 May 2008 00:00:00 PDT
Can a blood test improve treatment outcomes for colorectal cancer patients? Recently published studies indicate that personalized chemotherapy dose management -- measuring drug levels in patients' blood and adjusting them for optimal dosing -- can substantially reduce severe toxicity and improve efficacy in colorectal cancer. A Phase III randomized study of 208 colorectal cancer patients, by Erick Gamelin, M.D., Ph.D. et. al.
Does 1q31.1-32.1 Harbor A Tumor Suppressor Gene Related To Chinese SCC Patients? published
Thu, 01 May 2008 05:00:00 PDT
The LOH analysis on sporadic carcinoma by means of microsatellite markers has become an effective way to find allelic deletion regions and then to find candidate tumor suppressor genes. In a previous study, it was found that D1S413 (1q31.1-32.1, 9.8cM) exhibited higher LOH frequencies, which indicated that the region might harbor the putative tumor suppressor gene(s).
Small Study Finds Discrepancies Between Black Women's Recollection Of Receiving Some Health Screening Tests And Their Medical Records published
Wed, 30 Apr 2008 06:00:00 PDT
There are significant discrepancies in black women's recollection of having had health screenings -- including tests for breast, cervical and colon cancer -- and their medical records, according to a small study published in the journal Oncology Nursing Forum, Reuters Health reports.
$450,000 Sweetener In Colon Cancer Battle published
Mon, 28 Apr 2008 00:00:00 PDT
UK-based Association for International Cancer Research this week announced it will fund a Griffith University project led by Dr Joe Tiralongo to further develop a potential anti-cancer treatment that had shown promising results in lab tests.The grant will enable the team to test a range of new 'designer' compounds on tumours in living cells.
Study Examines Factors Affecting Low Rates Of Colorectal Screening Among Korean-Americans published
Fri, 25 Apr 2008 08:00:00 PDT
"Colorectal Cancer Screening Among Underserved Korean-Americans in Los Angeles County," Journal of Immigrant and Minority Health: Among Korean-Americans ages 40 to 70 in Los Angeles County, Calif.
Standard Anal Canal Cancer Treatment Preferred Over Experimental Drug published
Wed, 23 Apr 2008 13:00:00 PDT
An article published in JAMA reports that forpatients with anal canal cancer, experimental chemotherapy treatmentwith the drug cisplatin (administered prior to othertreatments) failed to increase disease-free survival rates. Compared tothe standard treatment regimen, therapy with cisplatin also increasedthe likelihood of colostomy procedures.Commonly, the first treatment therapy for anal canal cancer ischemoradiation.
ACORN Presents Findings Of Collaborative Metastatic Colorectal Cancer Research published
Tue, 22 Apr 2008 00:00:00 PDT
On Tuesday, April 15th, Lee S. Schwartzberg, MD, FACP, President of the Accelerated Community Oncology Research Network, Inc. presented findings at the American Association for Cancer Research annual meeting in San Diego. The Phase II study tested a novel biologic agent in conjunction with chemotherapy used in colorectal cancer with encouraging interim results.
History Of Inherited Cancer Mutation In America published
Fri, 18 Apr 2008 04:00:00 PDT
A gene mutation responsible for the most common form of inherited colon cancer is older and more common than formerly believed, according to a recent study.The findings provide a better understanding of the spread and prevalence of the American Founder Mutation, a common cause in North America of Lynch syndrome, a hereditary cancer syndrome that greatly increases a person's risk for developing cancers of the colon, uterus and ovaries.
Sirtex Receives FDA Approval For FAST Clinical Trial published
Thu, 17 Apr 2008 05:00:00 PDT
Sirtex, a leading developer of targeted and innovative cancer therapies, has received FDA approval under Investigational Device Exemption to conduct the first clinical trial to evaluate the safety of concurrent administration of FOLFOX6 and bevacizumab, an anti-angiogenic, with Selective Internal Radiation Therapy (SIRT) using SIR-Spheres®1 microspheres (FAST) as first-line treatment of patients with colorectal cancer that has metastasized to the liver. Dennis L. Carter, M.D.
Pitt Researchers Receive Funding In Support Of Gastrointestinal Cancer Research published
Thu, 17 Apr 2008 02:00:00 PDT
For the third year in a row, University of Pittsburgh Cancer Institute researchers have received funding from the GIST Cancer Institute - a patient driven organization that funds research on gastrointestinal stromal tumors, or GISTs. These tumors occur in the gastrointestinal tract and are particularly difficult to treat over time. The $135,000 award supports the research of Anette Duensing, M.D.
Two Medical Societies Developing Colonoscopy Tracking Database published
Wed, 16 Apr 2008 09:00:00 PDT
The American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy are developing a database that tracks details of gastroenterologists' techniques while performing colonoscopies and other common procedures, the Wall Street Journal reports.
Gene Variants Indicate Opposite Survival Outcomes For Women And Men With Colon Cancer published
Wed, 16 Apr 2008 04:00:00 PDT
A new study by researchers at the University of Southern California (USC) has found evidence that supports gender-related differences in the development and survival of metastatic colon cancer.The study, which was published in the journal Cancer Research, found that specific gene variants linked to the development of colon cancer resulted in opposite survival outcomes for men and women.
Drug Combination Reduces Colon Cancer Risk With Reduced Toxic Side Effects published
Tue, 15 Apr 2008 05:00:00 PDT
Using a combination of a targeted cancer-fighting agent called DFMO and a low dose of an anti-inflammatory drug, UC Irvine researchers have reduced the risk of reoccurring colorectal polyps, an early sign of colon cancer, by as much as 95 percent with fewer toxic side effects.The study marks a breakthrough in the effort to combat colon cancer, the third leading cause of cancer in men and fourth in women, according to Dr. Frank L. Meyskens Jr., the Daniel G.
Smoking Is Related To Subset Of Colorectal Cancers published
Tue, 15 Apr 2008 04:00:00 PDT
According to research from a team of Mayo Clinic scientists, smoking puts older women at significant risk for loss of DNA repair proteins that are critical for defending against development of some colorectal cancers.
Low Dose DFMO Reduces Colon Cancer Risk Without Toxicity published
Tue, 15 Apr 2008 02:00:00 PDT
A combination of the targeted agent difluoromethylornithine (DFMO) at a low dose and sulindac, a non-steroidal anti-inflammatory drug (NSAID), reduces the risk of recurrent colorectal adenomas, an early sign of colon cancer, by up to 95 percent with less toxicity than with chemotherapy, researchers report. "There is a great hope that we will be able to prevent colon cancer effectively using this method.
Additive Anti-Tumor Activity Of NKTR-102 In Combination With Bevacizumab Highlighted In Positive Preclinical Data Presented At AACR Meeting published
Tue, 15 Apr 2008 00:00:00 PDT
Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: NKTR) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal cancer when co-administered with bevacizumab.
Cell Death In The Colon Influenced By Vitamin D And Calcium published
Mon, 14 Apr 2008 04:00:00 PDT
Researchers at Emory University are learning how vitamins and minerals in the diet can stimulate or prevent the appearance of colon cancer.Emory investigators will present their findings on biological markers that could influence colon cancer risk in three abstracts at the American Association for Cancer Research meeting in San Diego, April 12-16, 2008.
New Technique In Treating Patients With Liver Cancer Proves Effective published
Mon, 14 Apr 2008 02:00:00 PDT
Use of multipolar radiofrequency ablation in the treatment of colorectal liver metastases is effective and has a relatively low recurrence rate, according to a recent study conducted by researchers at Charité, Campus Benjamin Franklin in Berlin, Germany."Radiofrequency ablation (RFA) has become a widely used treatment option for patients with primary liver cancer and liver metastases from some primary tumors, if surgery is not an option.
Smoking Related To Subset Of Colorectal Cancers With Absent DNA Repair Proteins published
Mon, 14 Apr 2008 00:00:00 PDT
Smoking puts older women at significant risk for loss of DNA repair proteins that are critical for defending against development of some colorectal cancers, according to research from a team led by Mayo Clinic scientists.
)
|
|
